Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1α using PX-478

Neoplasia

Volumn 7, Issue 5, 2005, Pages 475-485

  Jordan, Bénédicte F ^a,b   Runquist, Matthew ^a   Raghunand, Natarajan ^a   Baker, Amanda ^c   Williams, Ryan ^c   Kirkpatrick, Lynn ^d   Powis, Garth ^c   Gillies, Robert J ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF ARIZONA   (United States)

^d Biomira Inc   (Canada)

Author keywords

Diffusion Magnetic Resonance Imaging; Dynamic Contrast Enhanced Magnetic Resonance Imaging; HT 29 tumors; Molecular imaging; PX 478

Indexed keywords

2 AMINO 3 [4' N,N BIS(2 CHLOROETHYL)AMINO]PHENYLPROPIONIC ACID N OXIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; GADOLINIUM PENTETATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PX 478; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG INHIBITION; HEMODYNAMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

EID: 20444430874     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04628     Document Type: Article

References (70)

1. Hoeckel M, Schienger K, Aral B, Mitza M, Schaffer U, and Vaupel P (1996). Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56, 4509-4515.
2. Moulder J and Rockwell S (1987). Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 5, 313-341.
3. Nordsmark M, Hoyer M, Keller J, Nielson OS, Jensen OM, and Overgaard J (1996). The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 35, 701-708.
4. Goonewardene TI, Sowter HM, and Harris AL (2002). Hypoxia-induced pathways in breast cancer. Micro Res Tech 59, 41-48.
5. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F, Wang J, Shindo M, Higashino F, Takeda K, Asaka M, Katoh H, Sugiyama T, Hosokawa M, and Kobayashi M (2003). Dominant-negative hypoxia-inducible factor-1α reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 162, 1283-1291.
6. Hanahan D and Folkman J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
7. Semenza GL (2000). HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Am Phys Soc 88, 1474-1480.
8. Powis G and Kirkpatrick L (2004). HIF-1α as a cancer drug target. Mol Cancer Ther 3, 647-654.
9. Wang G, Dong Z, Xu G, Yang Z, Shou C, Wang N, and Liu T (1998). The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. J Cancer Res Clin Oncol 124, 615-620.
10. Chilov D, Camneish G, Kvietikova I, Ziegler U, Gassmann M, and Wenger RH (1999). Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1α. J Cell Sci 112, 1203-1212.
11. Minchenko A, Salceda S, and Bauer T (1994). Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 40, 35-39.
12. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, and Poellinger L (1999). Regulation of the hypoxia-inducible factor-1α by the ubiquitin-proteosome pathway. J Biol Chem 274, 6519-6525.
13. Huang TT, Yasunami M, Carlson EJ, Gillespie AM, Reaume AG, Hoffman EK, Chan PH, Scott RW, and Epstein CJ (1997). Superoxide-mediated cytotoxicity in superoxide dismutase-deficient fetal fibroblasts. Arch Biochem Biophys 344, 424-432.
14. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, and Simons JW (1999). Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and metastases. Cancer Res 59, 5830-5835.
15. Giatromanolaki A, Koukourakis M, Sivridis E, Turley H, and Talks K (2001). Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic molecular profile of tumors and survival. Br J Cancer 85, 881-890.
16. Birner P, Schindl M, Obermair A, Breitenecker G, and Oberhuber G (2001). Expression of hypoxia-inducible factor-1 alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7, 1661-1668.
17. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, and van der Wall E (2003). Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97, 1573-1581.
18. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, and Semenza GL (2001). Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61, 2911-2916.
19. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, and Oberhuber G (2000). Over-expression of hypoxia-inducible factor-1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60, 4693-4696.
20. Semenza GL (2000). Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35, 71-103.
21. Zagzag D, Zhong H, Scalzetti J, Laughner E, Simons J, Semenza G (2000). Expression of hypoxia-inducible factor-1 alpha in brain tumors: association with angiogenesis, invasion and progression. Cancer 88, 2606-2618.
22. Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavenee WK, and Wiestler OD (1997). Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93, 109-117.
23. Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, and Nose T (1996). Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56, 2185-2190.
24. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, and Powis G (2004). Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 3 (3), 233-244.
25. Gillies RJ, Bhujwalla ZM, Evelhoch J, Garwood M, Neeman M, Robinson SP, Sotak CH, and Van Der Sanden B (2000). Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2 (1-2), 139-151.
26. Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen SM, Ross BD, and Swartz HM (2000). Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2 (1-2), 152-165.
27. Padhani AR (2002). Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 16 (4), 407-422.
28. Knopp MV, Giesel FL, Marcos H, von Tengg-Kobligk H, and Choyke P (2001). Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 12 (4), 301-308.
29. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, Ostrowitzki S, and Melnyk O (1997). Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 7 (1), 68-74.
30. Demsar F, Roberts TP, Schwickert HC, Shames DM, van Dijke CF, Mann JS, Saeed M, and Brasch RC (1997). A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution. Magn Reson Med 37 (2), 236-242.
31. Gossmann A, Okuhata Y, Shames DM, Helbich TH, Roberts TP, Wendland MF, Huber S, and Brasch RC (1999). Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR imaging in the rat: comparison of macromolecular and small-molecular contrast media-preliminary experience. Radiology 213 (1), 265-272.
32. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, Lu Y, and Brasch RC (1998). Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 171 (4), 941-949.
33. Su MY, Cheung YC, Fruehauf JP, Yu H, Nalcioglu O, Mechetner E, Kyshtoobayeva A, Chen SC, Hsueh S, McLaren CE, and Wan YL (2003). Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 18 (4), 467-477.
34. Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, and Kristjansen PE (2003). Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 9 (1), 355-362.
35. Bammer R (2003). Basic principles of diffusion-weighted imaging. Eur J Radiol 45 (3), 169-184.
36. 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 73 (1), 61-64.
37. 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response. Cancer Res 58 (17), 3791-3799.
38. Poptani H, Puumalainen AM, Grohn OH, Loimas S, Kainulainen R, Yla-Herttuala S, and Kauppinen RA (1998). Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 5 (2), 101-109.
39. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, and Ross BD (2000). Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92 (24), 2029-2036.
40. Mardor Y, Roth Y, Lidar Z, Jenas T, Pfeffer R, Maier SE, Faibel M, Nass D, Hadani M, Orenstein A, Cohen JS, and Ram Z (2001). Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 61 (13), 4971-4973.
41. Mardor Y, Roth Y, Ochershvilli A, Spiegelmann R, Tichler T, Daniels D, Maier SE, Nissim O, Ram Z, Baram J, Orenstein A, and Pfeffer R (2004). Pretreatment prediction of brain tumors response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia 6 (2), 136-142.
42. Norris DG (2001). The effects of microscopic tissue parameters on the diffusion weighted magnetic resonance imaging experiment. NMR Biomed 14 (2), 77-93.
43. Kauppinen RA (2002). Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed 15 (1), 6-17.
44. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ, Johnson TD, Junck L, Robertson PL, Muraszko KM, Dong Q, Meyer CR, Bland PH, McConville P, Geng H, Rehemtulla A, and Chenevert TL (2003). Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2 (6), 581-587.
45. Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, and Gillies RJ (1999). Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1 (2), 113-117.
46. Jennings D, Hatton BN, Quo J, Galons JP, Trouard TP, Raghunand N, Marshall J, and Gillies RJ (2002). Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 4 (3), 255-262.
47. Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Mooreb J, Gillies RJ, and Stopeck A (2005). Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia (in press).
48. Trouard TP, Theilmann RJ, Altbach MI, and Gmitro AF (1999). High-resolution diffusion imaging with DIFRAD-FSE (diffusion-weighted radial acquisition of data with fast spin-echo) MRI. Magn Reson Med 42 (1), 11-18.
49. Lyng H, Haraldseth O, and Rofstad EK (2000). Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43 (6), 828-836.
50. Marzola P, Degrassi A, Calderan L, Farace P, Crescimanno C, Nicoiato E, Giusti A, Pesenti E, Terron A, Sbarbati A, Abrams T, Murray L, and Osculati F (2004). In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 10, 739-750.
51. Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N, Cohen RL, and Brasch RC (1998). Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16 (4), 225-230.
52. Roberts TP, Turetschek K, Preda A, Novikov V, Moeglich M, Shames DM, Brasch RC, and Weinmann HJ (2002). Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. Acad Radiol 9, S511-S513.
53. Turetschek K, Preda A, Floyd E, Shames DM, Novikov V, Roberts TP, Wood JM, Fu Y, Carter WO, and Brasch RC (2002). MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model. Acad Radiol 2, S519-S520.
54. Checkley D, Tessier JJ, Kendrew J, Waterton JC, and Wedge SR (2003). Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89 (10), 1889-1895.
55. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Bryne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, and Steward WP (2003). Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21 (21), 3955-3964.
56. Turetschek K, Preda A, Floyd E, Shames DM, Novikov V, Roberts TP, Wood JM, Fu Y, Carter WO, and Brasch RC (2003). MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model. Eur J Nucl Med Mol Imaging 30 (3), 448-455.
57. Gossmann A, Helbich TH, Kuriyama N, Ostrowitzki S, Roberts TP, Brasch RC, van Bruggen N, Wendland MF, Israel MA, and Brasch RC (2002). Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 15 (3), 233-240.
58. Kiessling F, Farhan N, Lichy MP, Vosseler S, Heilmann M, Krix M, Bohlen P, Miller DW, Mueller MM, Semmler W, Fusenig NE, and Delorme S (2004). Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 6 (3), 213-223.
59. Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, and Roberts TP (2004). Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 20 (1), 138-144.
60. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, and Zwierzina H (2002). Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94 (19), 1484-1493.
61. Wong MP, Cheung N, Yuen ST, Leung SY, and Chung LP (1999). Vascular endothelial growth factor is upregulated in early premalignant stage of colorectal tumour progression. Int J Cancer 81, 845-850.
62. Okamoto K, Oshika Y, Fukushima Y, Yoshimura M, Ohnishi Y, Tokunaga T, Hashimoto T, Hatanaka H, Tomii Y, Yoshida Y, Miura S, Tsuchida T, Kijima H, Yamazaki H, Nakamura M, and Ueyama Y (1999). Inhibition of liver metastasis of colon cancer by in vivo administration of anti-vascular endothelial growth factor antibody. Oncol Rep 6 (3), 553-556.
63. 2 tension. Proc Natl Acad Sci USA 92, 5510-5514.
64. Yonemura Y, Endo Y, Fujita H, Fishida S, Ninomiya I, Bandou E, Taniguchi K, Miwa K, Ohoyama S, Sugiyama K, and Sasaki T (1999). Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 5, 1823-1829.
65. Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, and Steward WP (2003). Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 30 (3), 32-38.
66. Helmer KG, Meiler MR, Sotak CH, and Petruccelli JD (2003). Comparison of the return-to-the-origin probability and the apparent diffusion coefficient of water as indicators of necrosis in RIF-1 tumors. Magn Reson Med 49 (3), 468-478.
67. Stegman LD, Rehemtulla A, Hamstra DA, Rice DJ, Jonas SJ, Stout KL, Chenevert TL, and Ross BD (2000). Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther 7 (12), 1005-1010.
68. Beauregard DA, Pedley RB, Hill SA, and Brindle KM (2002). Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15 (2), 99-105.
69. Sinha S and Sinha U (2002). Functional magnetic resonance of human breast tumors: diffusion and perfusion imaging. Ann N Y Acad Sci 980, 95-115.
70. DeVries AF, Kremser C, Hein PA, Griebel J, Krezcy A, Ofner D, Pfeiffer KP, Lukas P, and Judmaier W (2003). Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 15; 56 (4), 958-965.